{"nctId":"NCT00733135","briefTitle":"Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)","startDateStruct":{"date":"2008-10"},"conditions":["Peripheral Arterial Disease"],"count":133,"armGroups":[{"label":"Atherectomy with embolic protection","type":"OTHER","interventionNames":["Device: SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device"]}],"interventions":[{"name":"SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provides written informed consent\n* Willing to comply with follow-up evaluations at specified times\n* Has leg pain due to peripheral arterial disease\n* Disease located within the femoropopliteal artery\n* Moderate to severe calcification\n\nExclusion Criteria:\n\n* Previously implanted stent(s) or stent graft(s) in target leg\n* Life expectancy less than 12 months\n* Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Successful Revascularization","description":"Less than or equal to 50% residual diameter stenosis following plaque excision remaining at the target lesion(s), as adjudicated by the angiographic core laboratory","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Major Adverse Event Free Rate 30 Days","description":"MAE was defined as a serious adverse event that results in death, acute myocardial infarction, dissection (grade C or greater), clinical perforation, pseudo-aneurysm, thrombosis, distal embolism (clinically relevant), amputation, or clinically-driven target vessel revascularization (TVR), through 30 days post-procedure, as adjudicated by the Clinical Events Committee (CEC).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Technical Procedural Success","description":"Technical Procedural Success was defined as meeting all of the following requirements:\n\n* Less than or equal to 50% residual diameter stenosis at the target lesion(s), as adjudicated by the angiographic core laboratory\n* No procedure-related Major Adverse Events (MAE), as adjudicated by the Clinical Events Committee (CEC)\n* No device malfunction causing the procedure to be aborted\n* Successful delivery and placement of the SpiderFX™ embolic protection device","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Residual Diameter Stenosis","description":"This endpoint was met when there was less than 30% residual diameter stenosis following treatment with SilverHawk™ /TurboHawk™ plaque excision systems and any adjunctive therapy (if required), as adjudicated by the angiographic core laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Debris in Deployed SpiderFx™ Embolic Protection Device","description":"Presence of debris in deployed SpiderFx™ embolic protection device","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Preservation of Run-off Distal to the Filter","description":"Preservation of run-off distal to SpiderFX™ distal embolic protection device was determined by angiography of run-off vessels at the end of the procedure, as adjudicated by the angiographic core laboratory.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":133},"commonTop":["Dissection, grade A or B; target vessel","Other","Access site adverse event"]}}}